Uncategorized
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is raspberry hibiscus. And here is a helpful tip: A teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology, STAT writes. The deal is the latest in a run of biopharma acquisitions in recent months, as large and even midsize companies have been looking to bolster their pipelines as some of their key products face looming generic competition. This latest deal is one of the largest in the recent buying spree, and GSK’s largest in years. Nuvalent designs targeted cancer therapies, with two molecules both under U.S. Food and Drug Administration review for types of non-small cell lung cancer. They could be approved this year. The deal will give GSK, which has focused on gynecologic cancers as well as multiple myeloma, a broader lung cancer portfolio.
Merck and Gilead Sciences disclosed that an experimental long-acting pill combining two HIV medicines had met its primary efficacy goal in final-stage trials, Bloomberg News notes. The companies said that in two large trials, a once-weekly combination pill containing Merck’s islatravir and Gilead’s lenacapavir had proven to be “non-inferior” to standard pill regimens that are taken daily. If approved by regulators, the new combination could become the first once-weekly pill for the treatment of HIV. A once-weekly pill would provide a less-frequent dosing option that does not require an injection. Gilead currently sells a different version of lenacapavir as a twice-yearly injectable to prevent the disease under the brand name Yeztugo.
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is raspberry hibiscus. And here is a helpful tip: A teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology, STAT writes. The deal is the latest in a run of biopharma acquisitions in recent months, as large and even midsize companies have been looking to bolster their pipelines as some of their key products face looming generic competition. This latest deal is one of the largest in the recent buying spree, and GSK’s largest in years. Nuvalent designs targeted cancer therapies, with two molecules both under U.S. Food and Drug Administration review for types of non-small cell lung cancer. They could be approved this year. The deal will give GSK, which has focused on gynecologic cancers as well as multiple myeloma, a broader lung cancer portfolio.
Merck and Gilead Sciences disclosed that an experimental long-acting pill combining two HIV medicines had met its primary efficacy goal in final-stage trials, Bloomberg News notes. The companies said that in two large trials, a once-weekly combination pill containing Merck’s islatravir and Gilead’s lenacapavir had proven to be “non-inferior” to standard pill regimens that are taken daily. If approved by regulators, the new combination could become the first once-weekly pill for the treatment of HIV. A once-weekly pill would provide a less-frequent dosing option that does not require an injection. Gilead currently sells a different version of lenacapavir as a twice-yearly injectable to prevent the disease under the brand name Yeztugo.
Uncategorized
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
Updated June 11, 2026
WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.
“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.
Updated June 11, 2026
WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.
“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
Uncategorized
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.
But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.
WASHINGTON — Health secretary Robert F. Kennedy Jr. on Wednesday pointed to his “publicly available calendar” as an example of his commitment to transparency and to beat back unfavorable reporting.
But no such calendar, detailing who Kennedy meets with or how he spends his time, has been released by the administration. STAT has been asking the Department of Health and Human Services for Kennedy’s calendar for more than a year, via Freedom of Information Act requests and emails to the press office.
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
Nonprofit buys experimental cancer drug to maintain patient access
Potential Cocaine Addiction Targets Identified Through Genetic Mapping in Rats
New mRNA Delivery Platform Restores Muscle Function in DMD Models
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years ago
The old and New Edition cast comes together to perform